Although uterine distension in rats results in an escape reflex, there exists no model of uterine cervical distension (UCD), the pain stimulus during the first stage of labor. The aims of this study were to develop such a model in virgin rats and to test whether peripherally restricted kappa opioid receptor (KOR) agonists (ADL 10-0101, ADL 10-0102, ADL 10-0116) inhibit responses to UCD. Under intravenous (i.v.) pentobarbital and alpha-chloralose anesthesia, fine metal rods were inserted in both uterine cervical osses through a small midline laparotomy. UCD was performed by manual separation of the rods (25-100 g). Single-unit afferent responses in hypogastric nerve or reflex rectus abdominis electromyographic (EMG) activity were determined before and after i.v. KOR agonists. UCD resulted in a stimulus-dependent increase in single-unit afferent activity. Units could be characterized as low threshold (mean threshold 6.6+/-2.7 g), or high threshold (mean threshold 55+/-8.8 g); all were C fibers, all responded to topical bradykinin. ADL 10-0116 (10 mg/kg) reduced the afferent response to UCD. Reflex EMG response occurred over a distension force range of 25-100 g, unaffected by i.v. saline. All three KOR agonists produced a dose-dependent, naloxone-reversible inhibition of the EMG response with a potency relationship of ADL 10-0102 (ED50 0.04 mg/kg)>ADL 10-0101 (ED50 0.65 mg/kg)=ADL 10-0116 (ED50 0.60 mg/kg). These data support the use of acute UCD as a noxious stimulus, inducing afferent and reflex activity. Like other visceral stimuli, UCD is sensitive to inhibition by KOR agonists.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0304-3959(01)00398-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular mechanisms of inverse agonism via κ-opioid receptor-G protein complexes.
Nat Chem Biol
January 2025
The Bridge Institute, Michelson Center for Convergent Biosciences, University of Southern California, Los Angeles, CA, USA.
Opioid receptors, a subfamily of G protein-coupled receptors (GPCRs), are key therapeutic targets. In the canonical GPCR activation model, agonist binding is required for receptor-G protein complex formation, while antagonists prevent G protein coupling. However, many GPCRs exhibit basal activity, allowing G protein association without an agonist.
View Article and Find Full Text PDFThe endogenous dynorphin/kappa opioid receptor (KOR) system in the brain mediates the dysphoric effects of stress, and KOR antagonists may have therapeutic potential for the treatment of drug addiction, depression, and psychosis. One class of KOR antagonists, the long-acting norBNI-like antagonists, have been suggested to act by causing KOR inactivation through a cJun-kinase mechanism rather than by competitive inhibition. In this study, we screened for other opioid ligands that might produce norBNI-like KOR inactivation and found that nalfurafine (a G-biased KOR agonist) and nalmefene (a KOR partial agonist) also produce long-lasting KOR inactivation.
View Article and Find Full Text PDFGPR88 impairs the signaling of kappa opioid receptors in a heterologous system and in primary striatal neurons.
Neuropharmacology
March 2025
Network Center for Biomedical Research in Neurodegenerative Diseases. CiberNed., Spanish National Health Institute Carlos iii, Av. Monforte de Lemos, 3-5, 28029, Madrid, Spain; Molecular Neurobiology Laboratory, Dept. Biochemistry and Molecular Biomedicine, Facultat de Biologia, Universitat de Barcelona, 08028, Barcelona, Spain; School of Chemistry, Universitat de Barcelona, Barcelona, Spain. Electronic address:
Article Synopsis
- GPR88 is an orphan G protein-coupled receptor primarily found in the striatum, and its function is not well understood despite changes in its expression seen in Parkinson's disease models.
- GPR88 was found to interact with the kappa-opioid receptor (KOR), and this interaction inhibits KOR-mediated signaling, as evidenced by experiments showing that GPR88 can modulate effects of KOR agonists in both cultured cells and primary striatal neurons.
- The GPR88-KOR complexes were more common in specific neurons related to dopamine pathways, suggesting that understanding their relationship could have implications for conditions like neuropathic pain, Parkinson's disease, and neuropsychiatric disorders.
Microdosing of a kappa opioid receptor agonist within proximal nucleus accumbens shell microstructures revealing opposing behavioral outcomes.
Neuroscience
December 2024
Department of Psychiatry, Harvard Medical School, Basic Neuroscience Division, McLean Hospital, Boston, MA, USA.
Article Synopsis
- Targeted drug delivery to specific brain areas is difficult due to the complex differences in neuron types and functions.
- A new miniaturized implantable system allows for precise drug administration, enabling adjustments to therapies in real-time.
- Activating kappa opioid receptors in a specific brain region can create positive or negative responses, highlighting the importance of accuracy in drug delivery for potential therapies.
Preclinical evaluation of abuse potential of the peripherally-restricted kappa opioid receptor agonist HSK21542.
Regul Toxicol Pharmacol
December 2024
Saifu Laboratories Co., Ltd., Beijing, China; SAFE Medical Technology Co., Ltd., Hebei, China. Electronic address:
Article Synopsis
- HSK21542 is a kappa opioid receptor (KOR) agonist designed for pain relief and has been assessed for its potential for abuse prior to approval.
- The preclinical studies involved various tests in rats, including self-administration, drug discrimination, conditioned place preference, and withdrawal assessments, to evaluate its reinforcing effects and dependence potential.
- Results indicated that HSK21542 showed no behavioral signs of abuse or dependence, suggesting it has a low potential for abuse in humans.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!